文献速递临床试验与 GCP

高精度立体定向放疗治疗局灶性药物难治性癫痫对比标准治疗:随机等待对照试验(PRECISION试验)

High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial).
PubMed 文献 · Trials · 2024-05-21

PRECISION试验是一项等待对照的3期随机试验,纳入≥18岁、不适合开放手术的局灶性药物难治性癫痫患者,1:1随机接受单次24 Gy立体定向放疗(SRT)或继续抗癫痫药物及神经调控的标准治疗,主要目的是评估SRT能否在治疗2年后显著减少癫痫发作频率。

要点

  • 不适合开放手术的局灶性药物难治性癫痫患者,标准治疗为继续抗癫痫药物和神经调控,仅降低严重程度而不能治愈。
  • SRT为单次24 Gy基于直线加速器的立体定向放疗,靶区为所有(无)创检查定义的致痫区。
  • 等待对照组在2年随访后也接受SRT;试验同时评估SRT的成本效益。

核心结论

  • 作者假设对于不适合开放手术的局灶性药物难治性癫痫患者,SRT优于姑息性标准治疗,可在2年随访时使50%的患者达到75%的发作频率减少。
  • 这是首个比较SRT与标准治疗的随机试验,主要目的是确定SRT是否在治疗2年后显著减少癫痫发作频率。

研究设计与样本

  • 等待对照的3期随机临床试验,参与者按1:1比例随机分配接受SRT或标准治疗(继续抗癫痫药物和神经调控)。
  • 纳入年龄≥18岁、患有局灶性药物难治性癫痫且治疗前定义的致痫区不适合开放手术的患者。
  • 随机接受标准治疗的患者(等待对照组)在2年随访后被提供SRT。

主要发现

  • 既往研究显示SRT在该患者人群中具有良好前景,但该干预在荷兰尚不可用且未获报销。
  • SRT为基于直线加速器的单次24 Gy立体定向放疗,靶区为所有(无)创检查定义的致痫区。
  • 癫痫发作频率通过每日电子日记和夜间自动发作检测系统监测。
  • 潜在副作用通过先进MRI、认知评估、常见毒性标准和患者报告结局问卷评估。
  • 同时评估SRT治疗的成本效益。

关键数值与推荐

  • 主要目标为确定SRT是否在治疗2年后显著减少癫痫发作频率。
  • 作者假设SRT可使50%的患者在2年随访时达到75%的发作频率减少。

临床怎么用

  • 试验结果可能影响荷兰当前临床实践及 focal drug-resistant epilepsy 不适合开放手术患者的医疗费用报销,提供一种非侵入性可能治愈的治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The standard treatment for patients with focal drug-resistant epilepsy (DRE) who are not eligible for open brain surgery is the continuation of anti-seizure medication (ASM) and neuromodulation. This treatment does not cure epilepsy but only decreases severity. The PRECISION trial offers a non-invasive, possibly curative intervention for these patients, which consist of a single stereotactic radiotherapy (SRT) treatment. Previous studies have shown promising results of SRT in this patient population. Nevertheless, this intervention is not yet available and reimbursed in the Netherlands. We hypothesize that: SRT is a superior treatment option compared to palliative standard of care, for patients with focal DRE, not eligible for open surgery, resulting in a higher reduction of seizure frequency (with 50% of the patients reaching a 75% seizure frequency reduction at 2 years follow-up). METHODS: In this waitlist-controlled phase 3 clinical trial, participants are randomly assigned in a 1:1 ratio to either receive SRT as the intervention, while the standard treatments consist of ASM continuation and neuromodulation. After 2-year follow-up, patients randomized for the standard treatment (waitlist-control group) are offered SRT. Patients aged ≥ 18 years with focal DRE and a pretreatment defined epileptogenic zone (EZ) not eligible for open surgery will be included. The intervention is a LINAC-based single fraction (24 Gy) SRT treatment. The target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations. The seizure frequency will be monitored on a daily basis using an electronic diary and an automatic seizure detection system during the night. Potential side effects are evaluated using advanced MRI, cognitive evaluation, Common Toxicity Criteria, and patient-reported outcome questionnaires. In addition, the cost-effectiveness of the SRT treatment will be evaluated. DISCUSSION: This is the first randomized trial comparing SRT with standard of care in patients with DRE, non-eligible for open surgery. The primary objective is to determine whether SRT significantly reduces the seizure frequency 2 years after treatment. The results of this trial can influence the current clinical practice and medical cost reimbursement in the Netherlands for patients with focal DRE who are not eligible for open surgery, providing a non-invasive curative treatment option. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT05182437. Registered on September 27, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zegers CML, Swinnen A, Roumen C, et al. High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial). Trials. 2024. PMID: 38773643. doi:10.1186/s13063-024-08168-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。